Rybelsus vs. Qsymia

See how Rybelsus and Qsymia compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Rybelsus is FDA-approved for blood sugar control and cardiovascular risk reduction in type 2 diabetes, while Qsymia is FDA-approved specifically for chronic weight management.

  • Rybelsus is a once-daily oral tablet with no abuse potential, while Qsymia is a Schedule IV controlled substance dispensed only through certified REMS pharmacies.

  • Using Rybelsus for weight loss is off-label, whereas Qsymia carries a labeled indication for that exact purpose.

Rybelsus vs. Qsymia Drug Summary

Rybelsus

Rybelsus is an oral GLP-1 receptor agonist that helps control blood sugar in adults with type 2 diabetes and can lower cardiovascular risk in those with existing heart disease. It contains the same active ingredient as injectable Ozempic but comes as a once-daily tablet taken on an empty stomach. Doctors sometimes prescribe it off-label for weight loss in people without diabetes.

Qsymia

Qsymia combines phentermine, a stimulant that suppresses appetite, with topiramate, an anticonvulsant that helps you feel full, in one once-daily capsule. It is FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition, and in adolescents 12 and older. The dose is increased gradually over about 16 weeks to reach the target maintenance level.

Rybelsus vs. Qsymia Side Effects

Rybelsus

Most common
nausea (up to 20%)
abdominal pain (up to 11%)
diarrhea (up to 10%)
decreased appetite (up to 9%)

Qsymia

Most common
paresthesia (up to 21%)
dry mouth (up to 19%)
constipation (up to 16%)
insomnia (up to 11%)

Rybelsus vs. Qsymia Dosage

Rybelsus

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 3 mg once daily Days 1-30
Maximum dose 14 mg once daily Day 61 onward
Dose changes 2 increases Every 30 days

Qsymia

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 3.75 mg/23 mg once daily Days 1-14
Maximum dose 15 mg/92 mg once daily Week 17 onward
Dose changes 3 increases As tolerated

Rybelsus vs. Qsymia Indications

Rybelsus

Rybelsus is approved to improve blood sugar control in adults with type 2 diabetes and to reduce the risk of major cardiovascular events in those with existing heart disease. It is not approved for type 1 diabetes or for chronic weight management. Some clinicians prescribe it off-label for weight loss in people without diabetes.

  • Blood sugar control in type 2 diabetes

  • Cardiovascular risk reduction in adults with type 2 diabetes and heart disease

  • Off-label: weight loss in people without diabetes

  • Not approved for type 1 diabetes or chronic weight management

Qsymia

Qsymia is approved for chronic weight management in adults with obesity or in adults who are overweight with at least one weight-related condition, such as high blood pressure or type 2 diabetes. It is also approved for adolescents 12 and older with obesity. It is not approved for use during pregnancy or breastfeeding.

  • Chronic weight management in adults with obesity

  • Chronic weight management in overweight adults with a weight-related condition

  • Approved for adolescents 12 and older with obesity

  • Not approved for use in pregnancy or breastfeeding

Rybelsus vs. Qsymia Pros and Cons

Rybelsus

Rybelsus is well studied for blood sugar and cardiovascular outcomes in type 2 diabetes, but using it for weight loss alone is off-label and not FDA-approved. It avoids the abuse potential and REMS restrictions that come with Qsymia, though it carries its own boxed warning for thyroid tumors seen in animal studies.

Pros

  • Oral tablet, no injection required

  • FDA-approved for cardiovascular risk reduction in type 2 diabetes

  • Not a controlled substance

  • No REMS enrollment or pregnancy testing required

Cons

  • Not FDA-approved for weight loss; use for that purpose is off-label

  • Boxed warning for thyroid C-cell tumors seen in rodent studies

  • Typically costs more without insurance, roughly $998 to $1,029 a month

  • Must be taken on an empty stomach and wait 30 minutes before eating

Qsymia

Qsymia is FDA-approved specifically for chronic weight management, giving it a labeled indication Rybelsus lacks. As a controlled substance combining a stimulant and an anticonvulsant, it requires REMS enrollment, pregnancy monitoring, and watching for mood or cognitive side effects.

Pros

  • FDA-approved specifically for chronic weight management

  • Approved for adolescents 12 and older with obesity

  • Lower list price, roughly $200 to $350 a month

  • Non-injectable oral capsule

Cons

  • Schedule IV controlled substance with abuse potential

  • Requires REMS enrollment and dispensing through certified pharmacies

  • Contraindicated in pregnancy; monthly pregnancy testing recommended

  • Risk of mood changes, cognitive effects, and increased heart rate

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.